Lentiviral Vector Formulation for Freeze-Thaw and Agitation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lentiviral vector formulations face challenges in maintaining structural stability and biological activity under various conditions, including agitation, freeze/thaw cycles, and temperature fluctuations, leading to potential degradation and reduced potency.
Innovation Solution
Formulations comprising a TRIS-free buffer system, such as phosphate or histidine buffer, combined with a carbohydrate like sucrose, a surfactant like poloxamer or polysorbate, and a salt like NaCl, enhance lentiviral vector stability and suitability for systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If lentiviral vectors are stored under standard conditions, then they can be maintained for some period, but their structural integrity and biological activity degrade over time due to freeze/thaw cycles and temperature fluctuations
Solution Approach 1:
The patent modifies formulation parameters by using TRIS-free buffer systems (phosphate or histidine buffers), adjusting pH to specific ranges (6.0-7.5), and incorporating stabilizing excipients to enhance LV stability under varied storage conditions
Solution Approach 2:
The invention creates a composite formulation system combining TRIS-free buffer, carbohydrate (sucrose), surfactant (poloxamer or polysorbate), and salt (NaCl) that works synergistically to protect lentiviral vectors from degradation
2Stability of the object's composition
If surfactants are added to stabilize particle structures, then particle stability improves, but lipid membrane-bound particles may be destabilized
Solution Approach 1:
The patent specifies precise concentration ranges for surfactants (poloxamer or polysorbate) and TRIS-free buffer components to achieve the optimal balance between particle stability and lipid membrane integrity
Solution Approach 2:
The TRIS-free buffer system acts as an intermediary that mediates between the stabilizing effect of surfactants and the potential harmful effect on lipid membranes, enabling coexistence of both functions
3Stability of the object's composition
If pH is adjusted to stabilize lentiviral vectors, then structural integrity improves, but surface proteins may be destabilized and disassembly promoted
Solution Approach 1:
The patent optimizes pH to a specific range (6.0-7.5) and maintains this through TRIS-free buffer systems, achieving a delicate balance where structural integrity is stabilized while protein destabilization is prevented
Solution Approach 2:
The patent uses histidine or phosphate buffer systems that replicate the stabilizing effect of TRIS buffers without the harmful effect on proteins, effectively copying the beneficial property while eliminating the harm
Data Source
AI summary
Lentiviral vector (LV) formulations, and pharmaceutical compositions comprising such LV formulations, with improved stability and suitable for systemic administration are provided. Methods for treating disorders, especially blood disorders, using systemic administration of LV formulations are also provided.